Roche Takes Back Evotec's EVT-302 To Develop In Alzheimer's Disease, In $800 Million Deal

Evotec and Roche are to collaborate on the development of the MAO-B inhibitor, EVT-302, for Alzheimer's disease, a compound that previously failed in another indication, as an aid to smoking cessation.